Brief: Maat Pharma Announces Xervyteg's Phase 3 Dedicated Trial Launch In U.S Is Expected In 2026
19/06/2025 18:06
June 19 (Reuters) - Maat Pharma SA MAAT.PA: MAAT PHARMA : AS PART OF A STRATEGIC FOCUS ON XERVYTEG'S REGISTRATION ACTIVITIES IN EUROPE, PHASE 3 DEDICATED TRIAL LAUNCH IN U.S IS EXPECTED IN 2026 MAAT PHARMA: EMA MARKETING AUTHORIZATION APPLICATION OF XERVYTEG COULD BE EXPECTED IN H2 2026 Source text: ID:nBw1SK8QQa Further company coverage: MAAT.PA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Maat Pharma SA
See all newsBrief: MaaT Pharma Says FDA Indicates No Additional Nonclinical Studies Required For MaaT034 Safety
France's MaaT Pharma H1 operating loss widens on higher R&D costs
Brief: MaaT Pharma SA Receives 'Negative Trend' Opinion For Upcoming June CHMP Vote For MaaT013 (Xervyteg)
France's MaaT Pharma 2025 revenue rises 40.7% but misses expectations
Brief: MaaT Pharma Says Xervyteg Under EMA Review, Decision Expected In H2 2026